Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Alkermes | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Alkermes

Key commercial products up 22% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alkermes
 
2Q Revenues: $138.6 million (-9%)
 
2Q Earnings: $7.3 million (earnings were $22.4 million 2Q12)
 
Comments: Revenues from the company’s five key commercial products for the quarter grew 22% to $98.9 million. Manufacturing and royalty revenues from Risperdal Consta and Invega Sustenna/Xeplion were $56.2 million, up 16%. Manufacturing and royalty revenues from Ampyra/Fampyra were $19.9 million, up 16%. Net sales of Vivitrol were $17.4 million, up 40%. Royalty revenue from Bydureon was $5.4 million, up 80%. 2Q12 results included $20.0 million of intellectual property license revenue.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters